La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Active Biotech Croissance future

Future contrôle des critères 2/6

Active Biotech devrait augmenter ses bénéfices et ses revenus de 56% et 110.9% par an respectivement.

Informations clés

51.6%

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Biotechs croissance des bénéfices	46.8%
Taux de croissance des recettes	128.7%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	23 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Jun 05

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Jan 18

Prévisions de croissance des bénéfices et des revenus

OM:ACTI - Estimations futures des analystes et données financières antérieures (SEK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	40	0	N/A	0	1
12/31/2025	9	-41	N/A	-41	1
12/31/2024	N/A	-45	N/A	-47	1
6/30/2024	N/A	-44	-42	-42	N/A
3/31/2024	N/A	-45	-45	-45	N/A
12/31/2023	N/A	-46	-46	-46	N/A
9/30/2023	N/A	-48	-48	-48	N/A
6/30/2023	N/A	-51	-50	-50	N/A
3/31/2023	N/A	-54	-51	-51	N/A
12/31/2022	N/A	-58	-55	-55	N/A
9/30/2022	N/A	-60	-57	-57	N/A
6/30/2022	N/A	-57	-55	-55	N/A
3/31/2022	N/A	-56	-53	-53	N/A
12/31/2021	N/A	-50	-46	-46	N/A
9/30/2021	6	-38	-35	-35	N/A
6/30/2021	6	-35	-33	-33	N/A
3/31/2021	6	-32	-29	-29	N/A
12/31/2020	7	-32	-32	-32	N/A
9/30/2020	1	-39	-38	-38	N/A
6/30/2020	2	-40	-37	-37	N/A
3/31/2020	3	-36	-40	-40	N/A
12/31/2019	8	-34	-36	-36	N/A
9/30/2019	12	-32	-35	-35	N/A
6/30/2019	16	-31	-37	-37	N/A
3/31/2019	21	-35	-38	-38	N/A
12/31/2018	20	-37	-41	-41	N/A
9/30/2018	21	-88	-41	-41	N/A
6/30/2018	21	-88	-43	-43	N/A
3/31/2018	20	-103	N/A	-44	N/A
12/31/2017	20	-109	N/A	-46	N/A
9/30/2017	22	-63	N/A	-52	N/A
6/30/2017	21	-67	N/A	-57	N/A
3/31/2017	20	-59	N/A	-61	N/A
12/31/2016	19	-60	N/A	-73	N/A
9/30/2016	17	-86	N/A	-86	N/A
6/30/2016	18	-97	N/A	-123	N/A
3/31/2016	17	-152	N/A	-187	N/A
12/31/2015	16	-194	N/A	-218	N/A
9/30/2015	14	-210	N/A	-245	N/A
6/30/2015	12	-243	N/A	-256	N/A
3/31/2015	11	-229	N/A	-243	N/A
12/31/2014	10	-232	N/A	-267	N/A
9/30/2014	12	-257	N/A	-157	N/A
6/30/2014	116	-171	N/A	-159	N/A
3/31/2014	116	-194	N/A	-170	N/A
12/31/2013	116	-212	N/A	-102	N/A
9/30/2013	203	-130	N/A	-248	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ACTI devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ACTI devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ACTI devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ACTI ( 110.9% par an) devrait croître plus rapidement que le marché Swedish ( 1% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ACTI ( 110.9% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ACTI devrait être élevé dans 3 ans

Active Biotech Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

No longer forecast to breakeven

No longer forecast to breakeven

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target decreased to kr2.50

Recent updates

Active Biotech AB (Publ) Reports Intention Inaugural Interocular Concentrations Achieves in A Clinical Bylistribution Study of Laquinimod Eye Drops

No longer forecast to breakeven

Active Biotech Provides Update on the Clinical Phase Ib/IIa Study with Tasquinimod in Relapsed Refractory Multiple Myeloma

Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Active Biotech AB (publ) Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Active Biotech AB (publ), Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Active Biotech AB (Publ) Provides Update on the Scheduled Clinical Program for 2024

Active Biotech AB (Publ) Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee

Forecast breakeven date pushed back to 2025

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Forecast to breakeven in 2024

Active Biotech AB (publ) Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

New major risk - Share price stability

Insufficient new directors

Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma

Active Biotech AB (Publ) Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops

Active Biotech AB (publ) to Report First Half, 2023 Results on Aug 24, 2023

Active Biotech's Announces Nomination Committee

Forecast to breakeven in 2024

Active Biotech AB (publ) to Report Fiscal Year 2022 Results on Feb 09, 2023

Active Biotech AB (Publ) Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage

Active Biotech AB (publ) announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Price target decreased to kr2.50

High number of new and inexperienced directors

Active Biotech AB (publ) to Report Q3, 2022 Results on Nov 03, 2022

Active Biotech Announces First Patient Dosed in the Combination Part of the Phase Ib/IIa Study of Tasquinimod in Multiple Myeloma

Active Biotech AB (publ) Announces First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Active Biotech AB (publ) Provides Status Update of its Clinical Naptumomab Project

Independent Director recently bought kr60k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Active Biotech Receive Milestone Payment from Neotx

New 90-day low: kr1.44

Active Biotech AB Appoints Elaine Sullivan as A Director

New 90-day low: kr1.50

New 90-day low: kr1.98

New 90-day low: kr2.15

New 90-day low - kr2.48

Earnings released

New 90-day high - kr2.88

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance